<DOC>
	<DOC>NCT03053050</DOC>
	<brief_summary>The primary objective of this study is to evaluate whether selonsertib (SEL; GS-4997) can cause fibrosis regression and reduce progression to cirrhosis and associated complications in adults with NASH and bridging (F3) fibrosis.</brief_summary>
	<brief_title>Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>Key Liver biopsy consistent with NASH and bridging (F3 fibrosis) according to the NASH CRN classification in the opinion of the central reader Has the following laboratory parameters at the screening visit: Alanine aminotransferase (ALT) ≤ 8 x upper limit of normal (ULN) Creatinine Clearance (CLcr) ≥ 30 milliliter/minute (mL/min), as calculated by the CockcroftGault equation Hemoglobin A1c (HbA1c) &lt; 9.5% Total bilirubin ≤ 1.5 x ULN Key Prior history of decompensated liver disease including ascites, hepatic encephalopathy (HE), or variceal bleeding ChildPugh (CP) score &gt; 6, as determined at screening Model for Endstage Liver Disease (MELD) score &gt; 12, as determined at screening Other causes of liver disease including, but not limited to, alcoholic liver disease, hepatitis B, hepatitis C, autoimmune disorders, druginduced hepatotoxicity, Wilson disease, iron overload, and alpha1antitryspin deficiency, based on medical history and centralized review of liver histology. History of liver transplantation Current or history of hepatocellular carcinoma (HCC) Note: Other protocol defined Inclusion/Exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>